27.4 C
New York

Tag: cognitive

Online Assessment Software: How It Can Help HR Save Time

As of 2021, there were 7.2 million job openings in the US alone. In a month, there were over 6 million hires. This might...

Top News

Exploring Usability Principles of Efficiency and Self-evidency in Product Development

It was in the final semester when I was pursuing my Bachelor’s degree in psychology that I first heard the phrase, ‘User Experience Design’. Having no prior knowledge about the field, I applied for an Read more

The post Exploring Usability Principles of Efficiency and Self-evidency in Product Development appeared first on ixBlog.

Top 30 Wipro Interview Questions

Wipro Limited is a well-known multinational IT, consulting, and business process services company (NYSE: WIT, BSE: 507685, NSE: WIPRO). Wipro assists its clients in successfully adapting to the digital environment by utilizing cognitive computing, hyper-automation, robots, cloud, analytics, and emerging technologies. It has over 200,000 dedicated people who serve clients on six continents and is […]

The post Top 30 Wipro Interview Questions appeared first on GreatLearning Blog: Free Resources what Matters to shape your Career!.

stichd Selects Logility to Drive Supply Chain Growth and Attract Talent

LogDutch apparel licensing company to leverage the Logility ®Digital Supply Chain Platform to improve product availability and enhance employee experience ATLANTA – March 22, 2022 – Logility, Inc., a leader in supply chain innovation powering the sustainable and resilient enterprise, today announced stichd, a Netherlands-based product licensing company and division of PUMA, has chosen the Logility Digital […]

Why This Small New York District Is Rethinking Its Approach to Edtech Procurement

On a Native American reservation in the southwest corner of New York state sits Salamanca City Central School District. Marcy Brown is the Director of ...

Scientists Use AI to Trace the Origins of Psychedelic Experiences in the Brain

tech stories galaxy girl shielding eyes
For the past several decades, psychedelics have been widely stigmatized as dangerous illegal drugs. But a recent surge of academic research into their use to treat psychiatric conditions is spurring a shift in public opinion. Psychedelics are psychotropic drugs: substances that affect your mental state. Other types of psychotropics include antidepressants and anti-anxiety medications. Psychedelics […]

Report States That Cannabis Legalization Has Not Increased Youth Consumption

CPEAR released a report that discusses how cannabis legalization hasn’t led to increased youth consumption, and includes a list of recommendations on how to continue the effort.

The post Report States That Cannabis Legalization Has Not Increased Youth Consumption appeared first on High Times.

Tag Template - News Hub PRO

Leading Education Organizations Applaud Spending Increase for Social and Emotional Learning in FY2022 Consolidated Appropriations Act

Tag Template - News Hub PROMarch 17, 2022 — The Collaborative for Academic, Social, and Emotional Learning (CASEL) and Committee for Children strongly applaud the ... Read more

3 Primary Challenges while Designing Learning and Coaching Platforms

In today’s day and age where attention spans are dwindling, digital learning would be successful only if the user experience it offers is engaging and immersive. UX is a significant part of digital learning design, Read more

The post 3 Primary Challenges while Designing Learning and Coaching Platforms appeared first on ixBlog.

Riverside Insights Joins Forces with Renzulli Learning to Foster Instructional Equity through Engagement

Tag Template - News Hub PROITASCA, Ill. – March 16, 2022 – Riverside Insights®, a leading developer of research-based assessments and analytics, today announced a ... Read more

Can Cannabis Protect You From Cognitive Warfare?

Can Cannabis Protect You From Cognitive Warfare?

Can cannabis inoculate you from the Cognitive Warfare that’s currently going on?

The post Can Cannabis Protect You From Cognitive Warfare? appeared first on The Fresh Toast.

Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the...

Tag Template - News Hub PRO

TOKYO, Mar 11, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually.

The lecanemab data and additional research findings from Eisai's clinical development programs will be featured in 13 presentations. Lecanemab was granted Breakthrough Therapy and Fast Track designations by the U.S. Food and Drug Administration (FDA) in June and December 2021, respectively. Eisai anticipates completing lecanemab's rolling submission of a Biologics License Application for the treatment of early AD to the FDA under the accelerated approval pathway in the first quarter of Eisai's fiscal year 2022, which begins April 1, 2022. Additionally, the readout of the Phase 3 confirmatory Clarity AD clinical trial will occur in the Fall of 2022. Eisai initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data of lecanemab under the prior assessment consultation system in Japan in March 2022.

"Four key presentations at AD/PD 2022 advance our understanding of the mechanism of action of Eisai's investigational anti- Abeta protofibril antibody lecanemab and the therapy's clinical and safety profile, including amyloid related imaging abnormalities, or ARIA, from the Phase 2b study and open-label extension, in the potential treatment of early Alzheimer's disease," said Michael Irizarry, M.D., Senior Vice President, Deputy Chief Clinical Officer, Neurology Business Group, Eisai Inc. "In addition to lecanemab, Eisai's robust pipeline includes compounds targeting the tau pathway, other pathways leading to neurodegeneration, and the testing of combination therapies that may be the optimal approach to treat or even prevent Alzheimer's disease."

The focus on AD has historically been on alleviating cognitive, functional, and behavioral symptoms, but there has been significant progress in understanding the biological mechanisms of the disease. Eisai's investigational pipeline aims to treat the range of underlying pathophysiology, including amyloid, tau and neurodegeneration.

"Because of the robust design of the lecanemab Phase 2b study, Eisai was able to design the Phase 3 confirmatory Clarity AD clinical trial to optimally verify lecanemab's clinical efficacy and safety in early Alzheimer's disease," said Ivan Cheung, Chairman, Eisai Inc., Senior Vice President, President Neurology Business Group and Global Alzheimer's Disease Officer, Eisai Co., Ltd. "Part of the recruitment strategy for the Clarity AD confirmatory trial was to ensure greater inclusion of ethnic and racial populations. While there is still important work to be done in ensuring minority populations' participation in clinical trials, Eisai is proud that approximately 25% of the total U.S. enrollment in Clarity AD consists of African American and Hispanic persons living with early Alzheimer's disease, which mirrors the U.S. Medicare population."

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agent will successfully complete clinical development or gain health authority approval.

For more information, visit https://www.eisai.com/news/2022/news202218.html.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually.
Tag Template - News Hub PRO

Recent articles

spot_img